Verena Schroeder

List of Publications by Year
in descending order

48	1,514	279798	315739
papers	citations	23 h-index	38 g-index

48	48	48	1561
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An international collaborative study to assign value for Total Factor XIIIâ€B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen. Journal of Thrombosis and Haemostasis, 2022, 20, 525-531.	3.8	2
2	Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 1496-1506.	3.8	5
3	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
4	Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2021, 326, 332.	7.4	37
5	Laboratory Assessment of Coagulation Factor XIII. Hamostaseologie, 2020, 40, 467-471.	1.9	4
6	Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels. Neurology, 2020, 95, e898-e909.	1.1	18
7	Diabetes affects endothelial cell function and alters fibrin clot formation in a microvascular flow model: A pilot study. Diabetes and Vascular Disease Research, 2020, 17, 147916412090304.	2.0	9
8	Identification of amino acid residues that are crucial for FXIII-A intersubunit interactions and stability. Blood, 2020, 135, 145-152.	1.4	5
9	Role of complement in diabetes. Molecular Immunology, 2019, 114, 270-277.	2.2	31
10	MASP-1 of the complement system alters fibrinolytic behaviour of blood clots. Molecular Immunology, 2019, 114, 1-9.	2.2	12
11	Coagulation Factor XIII in Cerebral Venous Thrombosis. TH Open, 2019, 03, e227-e229.	1.4	3
12	Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes. International Journal of Molecular Sciences, 2019, 20, 5963.	4.1	6
13	Identification of a novel nonsense mutation leading to congenital factor XIII deficiency. Thrombosis Research, 2018, 165, 83-85.	1.7	3
14	Proline 36 of the Factor XIII Activation Peptide Plays a Crucial Role in Substrate Recognition and Zymogen Activation. Thrombosis and Haemostasis, 2018, 118, 2037-2045.	3.4	4
15	MASP-1 of the complement system enhances clot formation in a microvascular whole blood flow model. PLoS ONE, 2018, 13, e0191292.	2.5	31
16	Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. Thrombosis Research, 2017, 159, 96-99.	1.7	11
17	Factor XIII: Structure and Function. Seminars in Thrombosis and Hemostasis, 2016, 42, 422-428.	2.7	81
18	MASP-1 Induced Clotting â€“ The First Model of Prothrombin Activation by MASP-1. PLoS ONE, 2015, 10, e0144633.	2.5	27

#	Article	IF	Citations
19	MASP-1 of the complement system promotes clotting via prothrombin activation. Molecular Immunology, 2015, 65, 398-405.	2.2	53
20	Free factor <scp>XIII</scp> activation peptide affects factor <scp>XIII</scp> function. British Journal of Haematology, 2015, 168, 757-759.	2.5	5
21	Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. Diabetologia, 2014, 57, 1737-1741.	6.3	43
22	Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Molecular Immunology, 2014, 61, 69-78.	2.2	86
23	Complement C3 is a substrate for activated factor <scp>XIII</scp> that is crossâ€linked to fibrin during clot formation. British Journal of Haematology, 2013, 160, 116-119.	2.5	17
24	Factor XIII Deficiency: An Update. Seminars in Thrombosis and Hemostasis, 2013, 39, 632-641.	2.7	62
25	Acquired factor XIII deficiency: a therapeutic challenge. Thrombosis and Haemostasis, 2013, 109, 479-487.	3.4	53
26	Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diabetes and Vascular Disease Research, 2012, 9, 216-225.	2.0	79
27	Effects of MASP-1 of the Complement System on Activation of Coagulation Factors and Plasma Clot Formation. PLoS ONE, 2012, 7, e35690.	2.5	99
28	Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica, 2010, 95, 956-962.	3.5	44
29	Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events. Blood, 2010, 115, 5089-5096.	1.4	23
30	Thrombelastographic studies on factor XIII. Thrombosis and Haemostasis, 2010, 104, 1277-1279.	3.4	9
31	Coagulation factor XIII activation peptide and subunit levels in patients with acute ischaemic stroke: A pilot study. Thrombosis Research, 2010, 126, e122-e127.	1.7	13
32	Role of proteomic technologies in understanding risk of arterial thrombosis. Expert Review of Proteomics, 2009, 6, 539-550.	3.0	4
33	Relation of depression to various markers of coagulation and fibrinolysis in patients with and without coronary artery disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 782-787.	2.8	15
34	Factor XIII in severe sepsis and septic shock. Thrombosis Research, 2007, 119, 311-318.	1.7	25
35	International Registry on Factor XIII Deficiency: A basis formed mostly on European data. Thrombosis and Haemostasis, 2007, 97, 914-921.	3.4	129
36	Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thrombosis and Haemostasis, 2007, 97, 890-898.	3.4	26

#	Article	IF	Citations
37	Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thrombosis and Haemostasis, 2007, 97, 890-8.	3.4	7
38	International registry on factor XIII deficiency: a basis formed mostly on European data. Thrombosis and Haemostasis, 2007, 97, 914-21.	3.4	33
39	TAFI and PAI-1 levels in human sepsis. Thrombosis Research, 2006, 118, 205-212.	1.7	127
40	TAFI activity in coronary artery disease: A contribution to the current discussion on TAFI assays. Thrombosis and Haemostasis, 2006, 96, 236-237.	3.4	18
41	Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder. Thrombosis and Haemostasis, 2006, 95, 77-84.	3.4	38
42	Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder. Thrombosis and Haemostasis, 2006, 95, 77-84.	3.4	11
43	Nicorandil â€“ Review of Pharmacological Properties and Clinical Applications. Cardiology, 2005, 5, 220-229.	0.3	7
44	Factor XIII activation by thrombin depends on FXIIIVal34Leu genotype. Blood, 2003, 101, 371-371.	1.4	1
45	Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thrombosis and Haemostasis, 2003, 90, 434-438.	3.4	65
46	Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by Angiography. Thrombosis and Haemostasis, 2002, 88, 1020-1025.	3.4	66
47	Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thrombosis and Haemostasis, 2002, 88, 1020-5.	3.4	19
48	Influence of Blood Coagulation Factor XIII and FXIII Val34Leu on Plasma Clot Formation Measured by Thrombelastography. Thrombosis Research, 2001, 104, 467-474.	1.7	46